Abstract
Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management. Several studies have found cardioprotective effects of incretin-based therapies; however, it remains unclear whether there is any difference in heart failure (HF) risk between the two incretin-based therapies (DPP-4 inhibitors and GLP-1 receptor agonists). We aimed to assess the risk of hospitalization due to HF with the use of DPP-4 inhibitors compared to GLP-1 receptor agonists. Using Truven Health Marketscan data, we conducted a retrospective cohort study of patients with type 2 diabetes, who were newly initiated on DPP-4 inhibitors or GLP-1 agonists. Follow-up continued from drug initiation until the first occurrence of: HF hospitalization (primary outcome), discontinuation of therapy (i.e. no fill for 7 days), switch to the comparator, end of enrollment, or end of study (December 2013). Cox proportional hazards models with propensity-score-matching were used to compare the risk of HF hospitalization between DPP-4 inhibitors and GLP-1 agonists. A total of 321,606 propensity score-matched patients were included in the analysis (n = 160,803 for...Continue Reading
References
Nov 5, 1998·Statistics in Medicine·R B D'Agostino
Dec 25, 2003·Diabetes Care·Richard W NestoRichard Kahn
Jan 25, 2012·Pharmacoepidemiology and Drug Safety·Jane S SaczynskiJerry H Gurwitz
Jan 25, 2012·Pharmacoepidemiology and Drug Safety·Bruce FiremanJoe V Selby
Feb 11, 2012·Endocrine Reviews·John R Ussher, Daniel J Drucker
Aug 8, 2012·The Journal of Clinical Endocrinology and Metabolism·Adrian Vella
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Feb 7, 2014·International Journal of Clinical Practice·S Brunton
Feb 14, 2014·Cardiovascular Diabetology·Toru MiyoshiHiroshi Ito
Aug 2, 2014·Therapeutic Advances in Drug Safety·Thomas KaragiannisApostolos Tsapas
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Aug 13, 2015·Heart and Vessels·Takehiro HashikataJunya Ako
Jan 8, 2016·Diabetes Care·Alex Z FuJohn Sheehan
Feb 19, 2016·BMJ : British Medical Journal·Ling LiXin Sun
Apr 26, 2016·Annals of Internal Medicine·Sengwee TohBruce H Fireman
May 14, 2016·BMC Cardiovascular Disorders·Ling LiXin Sun
May 22, 2016·Diabetes Care·Kristian B Filion, Samy Suissa
Jul 16, 2016·European Heart Journal. Cardiovascular Pharmacotherapy·Faiez ZannadGonzalo Calvo
Feb 12, 2017·Cardiovascular Diabetology·Gian Paolo FadiniAngelo Avogaro
Apr 23, 2017·Diabetes & Metabolism·André J Scheen
Jun 24, 2017·Medicine·Hyouk-Jun ChinJu-Young Shin
Aug 2, 2017·Cardiovascular Diabetology·Santosh GautamJeff White
Sep 14, 2017·Circulation. Heart Failure·Young-Gun KimHae Jin Kim
Nov 9, 2017·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·P GargiuloP Perrone-Filardi
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Apr 21, 2018·JAMA : the Journal of the American Medical Association·Sean L ZhengKarim Meeran
Citations
May 27, 2020·International Journal of Clinical Practice·Raquel Herrera Comoglio, Xavier Vidal Guitart
Mar 12, 2020·Diabetes, Obesity & Metabolism·David R WebbMelanie J Davies
Jul 2, 2019·Molecular Medicine Reports·Xietian PanHaokao Gao
Aug 30, 2019·Cardiovascular Diabetology·Yue FeiBernard Man Yung Cheung
Sep 5, 2019·Cardiovascular Diabetology·Michael A NauckRury R Holman
Jun 24, 2020·Cardiovascular Diabetology·Osamah M AlfayezMajed S Al Yami
Apr 10, 2019·Cardiovascular Diabetology·Da-Ya YangXin-Xue Liao
Jul 8, 2020·Cardiovascular Diabetology·David TheinSøren Lund Kristensen
Apr 27, 2020·Cardiovascular Diabetology·Jie ZhangLi-Xin Guo
Nov 30, 2019·Cardiovascular Diabetology·Aya ShirakiKoichi Node
Jul 8, 2020·Cardiovascular Diabetology·Bo Liang, Ning Gu
May 1, 2021·Primary Care Diabetes·Omar S AlkheziOsamah M Alfayez